Skip to content

Effect evaluation test on intestinal microflora by barley tea drinking in persons with allergic symptoms

Effect evaluation test on intestinal microflora by barley tea drinking in persons with allergic symptoms - Effect evaluation test on intestinal microflora by barley tea drinking in persons with allergic symptoms

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000050072
Enrollment
24
Registered
2023-01-18
Start date
2023-01-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Interventions

Ingest 600 ml barley tea daily for 12 weeks. Ingest 500 ml water daily for 12weeks.

Sponsors

Akasaka Family Clinic
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document 2.Healthy Japanese who are 20 years old or more and under 65 years old

Exclusion criteria

Exclusion criteria: 1.Persons who are currently suffering from some kind of disease and are judged by the investigator to need treatment 2.Persons with severe anemia 3.Pregnant, lactating, pregnant 4.Persons who may cause allergic symptoms to the ingredients contained in the test food 5.Persons with alcoholism or other mental disorders 6.Persons who have a smoking habit 7.Persons with borderline diabetes or already diagnosed with diabetes 8.Persons who may change their lifestyle during the examination period (night shift, long trip, etc.) 9.Persons who plan to take new health foods or supplement foods during the examination period 10.Persons who have received hormone replacement therapy within the past 6 months 11.Persons who have been treated with hospitalization within the past 6 months 12.Persons who participate in other clinical studies or participated in the last 3 months or plan to participate in other clinical studies. 13.Persons who are judged by the investigator to be inappropriate for this study.

Design outcomes

Primary

MeasureTime frame
Stool test (intestinal flora, organic acids, spoilage products, and IgA) Saliva test (saliva s-IgA) Blood test (non-specific IgE, IgG, IgM, IgA, MAST 36) Measure at before and 12 weeks after ingestion.

Secondary

MeasureTime frame
Fasting blood index (total protein, albumin, total cholesterol, LDL cholesterol, HDL cholesterol, neutral fat, urea nitrogen, creatinine, uric acid, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-GTP) , bumin/globulin ratio (A/G ratio), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), leucine aminopeptidase (LAP), cholinesterase (CHE), creatinine phosphokinase (CPK), HbA1C, glucose, sodium , potassium, chlorine, calcium, magnesium, inorganic phosphorus, serum iron, blood count, ferritin) Body composition (body weight, BMI, lean body mass) Measure at before and 12 weeks after ingestion.

Countries

Japan

Contacts

Public ContactTakamasa Masuda

Healthcare Systems Co., Ltd. Clinical Research Department

masudat@hc-sys.jp0368092722

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026